Form 4: Karyopharm Therapeutics EVP Reshma Rangwala Sells Shares to Cover Tax Obligations

Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics, sold shares of common stock to cover withholding tax liabilities related to vesting restricted stock units.

Summary

• Reshma Rangwala, the EVP & Chief Medical Officer of Karyopharm Therapeutics Inc. (KPTI), reported the sale of company shares.
• The transactions occurred on February 29, 2024, and March 1, 2024.
• A total of 15,667 shares were sold on February 29, 2024, at a price of $1.17 per share.
• On March 1, 2024, 5,969 shares were sold at a price of $1.2 per share.
• The sales were executed under a pre-arranged automatic sale instruction plan adopted on April 4, 2022, to cover withholding tax obligations.
• Following these transactions, Rangwala directly owns 349,720 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating routine stock sales for tax purposes. It doesn't convey any particularly positive or negative sentiment about the company's prospects.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often related to compensation and tax planning. The fact that this sale was executed under a pre-arranged plan suggests it was not based on insider information or a change in the executive's outlook on the company.

Stakeholder Impact

• The stock sale may have a minor dilutive effect on existing shareholders.
• The sale is related to compensation for an employee.

Key Dates